Swissmedic
REGULATORY UPDATE
I-SMI.TI.22e Notifications according to Article 41, MPLO
Published: 9/23/2026Detected: 9/4/2026
Summary preview
Defines or clarifies Swiss regulatory expectations for notifications submitted under Article 41 of the MPLO framework.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#Swissmedic
#MPLO
#Article 41
#notifications
#regulatory submissions
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
- Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
- NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
- Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
- Save the Date: Clinical Trials Symposium 202711/4/2026